Clinical and Translational Oncology

, Volume 18, Issue 8, pp 813–824 | Cite as

CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review

  • G. CollocaEmail author
  • A. Venturino
  • I. Governato
Research Article


Various kinetic parameters, based on a minimum of two time points, have been built with CA125 determinations. The aim of this study is to review studies about the clinical application of CA125-related tumor cell kinetics variables in patients with advanced ovarian cancer (AOC) receiving chemotherapy. A literature search for studies about CA125-related variables in patients with AOC was undertaken on three databases, by predefined search criteria, and a selection of studies was performed. Sixty-two studies were selected. CA125-related variables were summarized in three groups: response-related, time-to-event, and other CA125-related tumor cell kinetics variables. Even though CA125 changes and half-life after chemotherapy were the most studied, other variables and two models have been well defined, and often showed an interesting power to predict survival. These kinetics variables are related to the CA125 regression curve, pre- and post-chemotherapy kinetics, or are variables inferred from a population model of CA125 kinetics.


CA125 Ovarian cancer Chemotherapy Tumor growth kinetics 


Compliance with ethical standards

This article does not contain studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Bast RC Jr, Feeney M, Lazarus H, Nadler RM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumour Biol. 2009;30:51–60.CrossRefPubMedGoogle Scholar
  5. 5.
    Kenesman P, Verstraeten AA, van Kamp GJ, von Mesdorff-Pouilly S. The second generation CA 125 assay. Ann Med. 1995;27:107–13.CrossRefGoogle Scholar
  6. 6.
    Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, Mc Cready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989;96:1395–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Van der Burg ME, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988;30:307–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand. 1990;69:423–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol. 2011;22(Suppl 8):viii49–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol. 1989;7:1667–71.PubMedGoogle Scholar
  15. 15.
    Sevelda P, Schemper M, Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obst Gynecol. 1989;161:1213–6.CrossRefGoogle Scholar
  16. 16.
    Markowska J, Manys G, Szewierski Z. CA, 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study. Eur J Gynaecol Oncol. 1992;13:201–4.PubMedGoogle Scholar
  17. 17.
    Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RC, Wilkinson P, et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological cancer. Int J Gynecol Cancer. 1993;3:285–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Frisken J, Leonard RCF, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, et al. The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br J Cancer. 1993;68:140–5.CrossRefGoogle Scholar
  19. 19.
    Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer. 1993;67:1361–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ron IG, Inbar M, Gelernter I, Lewysohn O, Ayalon D, Dale J, et al. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand. 1994;73:658–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric italian study. Gynecol Oncol. 1995;58:42–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Davelaar EM, Bonfrer JMG, Verstraeten RA, ten Bokkel Huinink WW, Kenemans P. CA125. A valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer. 1996;78:118–27.CrossRefPubMedGoogle Scholar
  23. 23.
    Ferrero J-M, Largillier M, Ramaioli A, Heudier P, Teissier E, Namer M. Valeur pronostique de la normalisation précoce du CA 125 au cours de la chimiothérapie des tumeurs de l’ovaire stades III et IV. Bull Cancer. 1997;84:722–8.PubMedGoogle Scholar
  24. 24.
    Munstedt K, Krisch M, Sachsse S, Vahrson H. Serum CA 125 levels and survival in advanced ovarian cancer. Arch Gynecol Obstet. 1997;259:117–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers. 2000;15:147–52.PubMedGoogle Scholar
  26. 26.
    Van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000;79:444–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Nelukova M, Pecen L, Kalabova R, Simickova M, Topolcan O, Pikner L, et al. Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125. Clin Chem. 2002;48:1364–7.Google Scholar
  28. 28.
    Markman M, Federico M, Liu P-Y, Hannigan E, Alberts D. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist. 2007;12(1):72–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Riedinger JM, Bonnetain F, Basuyau JP, Eche N, Larbre H, Dalifard I, et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol. 2007;18:881–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007;104:176–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Williams S, Gupta D, Dahik S, Dzike KE, Lambert GM, Lammersfeld CA. Significance of changes in serum CA125 level on overall survival in ovarian cancer. J Clin Oncol. 2009;27:e16546 (abstract).CrossRefGoogle Scholar
  33. 33.
    Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;114:242–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Gupta D, Lammersfeld CA, Vashi PG, Braun DP. Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer. J Ovarian Res. 2010;3:22.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gmyrek LJ, Jonska-Gmyrek JG, Kotowicz B, Linder B, Krynicki R, Staniaszek J, et al. The evaluation of prognostic value of CA125 tumor marker serum concentration in ovarian cancer patients. J Clin Oncol. 2010;28:90 (abstract).Google Scholar
  36. 36.
    Fader AN, Java J, Krivak TC, Bristow RE, Tergas AI, Bookman MA, et al. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2014;132:560–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Pelissier A, Bonneau C, Chereau E, de la Motte Rouge T, Fourchotte V, Darai E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2014;135:542–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Gard GB, Houghton CR. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol. 1994;53:283–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Rosman M, Hayden CL, Thiel RP, Chambers JT, Cohorn EI, Chambers SK, et al. Prognostic indicators for poor risk epithelial ovarian carcinoma. Cancer. 1994;74:1323–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005;16:47–50.CrossRefPubMedGoogle Scholar
  41. 41.
    Markman M, Liu P-Y, Rothenberg ML, Monk BJ, Brady M, Alberts DS. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24:1454–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17:1234–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol. 2008;19:327–31.CrossRefPubMedGoogle Scholar
  44. 44.
    Kang S, Seo S-S, Park S-Y. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer. J Surg Oncol. 2009;100:244–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Van Altena AM, Kolwijck E, Spanjer MJB, Hendriks JCM, Massuger LFAG, de Hullu JA. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol. 2011;119:265–9.CrossRefGoogle Scholar
  46. 46.
    Buller RE, Vasilev S, DiSaia PJ. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s. Am J Obstet Gynecol. 1996;174:1241–53.CrossRefPubMedGoogle Scholar
  47. 47.
    Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, et al. A risk model for ovarian carcinoma patients using CA 125. Cancer. 1996;77:1122–30.CrossRefPubMedGoogle Scholar
  48. 48.
    Liu P-Y, Alberts DS, Monk BJ, Brady M, Moon J, Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving manteinance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007;25:3615–20.CrossRefPubMedGoogle Scholar
  49. 49.
    Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, et al. Early decline in Cancer Antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst. 2011;103:1338–42.CrossRefPubMedGoogle Scholar
  50. 50.
    Willemse PHB, Aalders JG, de Bruyn HWA, Mulder NH, Sleijfer DT, de Vries EGE. CA-125 in ovarian cancer: relation between half-life, doubling time and survival. Eur J Cancer. 1991;8:993–5.CrossRefGoogle Scholar
  51. 51.
    Tsuda H, Hashiguchi Y, Nakata S, Deguchi M, Negoro S, Ishiko O, et al. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2002;12:435–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M, Scambia G. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2008;109:187–93.CrossRefPubMedGoogle Scholar
  53. 53.
    Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol. 1991;165:360–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer. 1984;50:765–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990;163:1164–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Markowska J, Kopczynski Z, Manys G, Szewierski Z. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment. Neoplasma. 1990;37:687–92.PubMedGoogle Scholar
  57. 57.
    Meier W, Stieber P, Fateh-Moghadam A, Eierman W, Hepp H. Prognostic significance of the CA 125 half-life for the further outcome of ovarian cancer. Geburtshilfe Frauenheilkd. 1992;52:528–32.CrossRefGoogle Scholar
  58. 58.
    Riedinger JM, Barillot I, Coudert B, Fargeot P, Berriolo-Riedinger A, Guerrin J. Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV. Bull Cancer. 1996;83:654–63.PubMedGoogle Scholar
  59. 59.
    Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol. 2004;93:131–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Mano A, Godinho I, Falcao AC. CA 125 half-life breakpoint between a “good” and “poor” prognosis in patients with ovarian cancer. Int J Gynecol Obstet. 2005;88:333–5.CrossRefGoogle Scholar
  61. 61.
    Tate S, Hirai Y, Takeshima N, Hasumi K. CA 125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol. 2005;96:143–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Han LY, Karavasilis V, van Hagen T, Nicum S, Thomas K, Harrison M, et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur J Cancer. 2010;46:1359–64.CrossRefPubMedGoogle Scholar
  63. 63.
    Riedinger JM, Bonnetain F, Eche N, Basuyau J-P, Wafflart J, Ricolleau G, et al. Valeur pronostique de la demi-vie du CA 125 et de sa normalisation précoce au cours de la chimiothérapie des tumeurs avancées de l’ovaire: résultats d’une étude multicentrique française. Bull Cancer. 2007;94:287–95.PubMedGoogle Scholar
  64. 64.
    Riedinger JM, Eche N, Basuyau JP, Dalifard I, Hacene K, Pichon MF. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol. 2008;109:194–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, et al. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011;284:221–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M. CA125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999;81(4):662–6.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Gardner GJ, Baser RE, Brady MF, Bristow RE, Markman M, Spriggs D, et al. CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol. 2012;124:216–20.CrossRefPubMedGoogle Scholar
  68. 68.
    Mano A, Falcao A, Godinho I, Santos J, Leitao F, Oliveira C, et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol. 2005;97:529–34.CrossRefPubMedGoogle Scholar
  69. 69.
    Uzunoglu S, Aybatli A, Kaplan PB, Cicin I, Sut N, Sayn C, et al. Assessment of CA125 area under the curve as a prognostic factor in patients with ovarian cancer. Med Oncol. 2013;30:447. doi: 10.1007/s12032-012-0447-x.CrossRefPubMedGoogle Scholar
  70. 70.
    Pearl ML, Yashar CM, Johnston CM, Reynolds K, Roberts JA. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol. 1994;53:339–43.CrossRefPubMedGoogle Scholar
  71. 71.
    Carcenac G, Georges A, Bordenave L. Modélisation de la cinétique du CA 125 sous chimiothérapie. Ann Biol Clin. 2004;62:99–102.Google Scholar
  72. 72.
    Hall MR, Petruckevitch A, Pascoe J, Persic M, Tahir S, Morgan JS, et al. Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer. Int J Gynecol Cancer. 2014;24:676–81.CrossRefPubMedGoogle Scholar
  73. 73.
    You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, et al. The strong prognostic value of KELIM, a model-based parameter from CA125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Onco. 2013;130:289–94.CrossRefGoogle Scholar
  74. 74.
    Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assessment of tumor response to therapy based on tumor growth kinetics. Br J Cancer. 2011;105:682–6.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Colloca G, Venturino A, Addamo G, Coccorullo Z, Ratti R, Caltabiano G, et al. CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation. Jpn J Clin Oncol. 2013;43:1203–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Wilbaux M, Henin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, et al. Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecol Oncol. 2014;133:460–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Chiang AJ, Chen J, Chung Y-C, Huang H-J, Liou WS, Chang C. A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer. J Gynecol Oncol. 2014;25:51–7.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Gundogdu F, Soylu F, Erkan L, Tatli O, Mavi S, Yavuzcan A. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Arch Gynecol Obstet. 2011;283:1397–402.CrossRefPubMedGoogle Scholar
  79. 79.
    Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. Cancer. 2009;115:1028–35.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Matte I, Lane D, Boivin M, Rancourt C, Pichè A. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer. 2014;14:234.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96:487–8.CrossRefPubMedGoogle Scholar
  82. 82.
    Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol. 2003;21:3013–5.CrossRefPubMedGoogle Scholar
  83. 83.
    Rustin GJS, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545–51.PubMedGoogle Scholar
  84. 84.
    Bridgewater JA, Nelstrop AE, Rustin GJS, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17:501–8.PubMedGoogle Scholar
  85. 85.
    Wilbaux M, Henin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, et al. Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. Br J Cancer. 2014;110:1517–24.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18:3084–92.PubMedGoogle Scholar
  87. 87.
    Rustin GJS, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054–7.PubMedGoogle Scholar
  88. 88.
    Vergote I, Rustin GJS, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MKB, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst. 2000;92:1534–5.CrossRefPubMedGoogle Scholar
  89. 89.
    Bast RC, Thigpen JT, Arbuck AG, Basen-Engquist K, Burke LB, Freedman R, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol. 2007;107:173–6.CrossRefPubMedGoogle Scholar
  90. 90.
    Vermorken JB, Parmar MK, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, et al. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol. 2005;16(Suppl 8):viii20–9.PubMedGoogle Scholar
  91. 91.
    Kaye SB, Colombo N, Monk J, Tjulandin S, Kong B, Roy M, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol. 2011;22:49–58.CrossRefPubMedGoogle Scholar
  92. 92.
    Sabbatini P, Mooney D, Iasonos A, Thaler H, Aghajanian C, Hensley M, et al. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. Int J Gynecol Oncol. 2007;17:589–94.CrossRefGoogle Scholar
  93. 93.
    Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer. 2012;106:633–7.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, et al. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006;103:212–8.CrossRefPubMedGoogle Scholar
  95. 95.
    Markman M. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008;113:2832–3.CrossRefPubMedGoogle Scholar
  96. 96.
    Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European–Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–66.PubMedGoogle Scholar
  97. 97.
    Markman M. The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy. Cancer. 2011;117:660–1.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  1. 1.Division of Medical Oncology“Giovanni Borea” HospitalSanremoItaly
  2. 2.Division of Medical Oncology“Santo Spirito” HospitalRomeItaly

Personalised recommendations